Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema


ERÇALIK N. Y., Imamoglu S., Kumral E. T., Yenerel N. M., Bardak H., Bardak Y.

Arquivos Brasileiros de Oftalmologia, cilt.79, sa.6, ss.373-375, 2016 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 79 Sayı: 6
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5935/0004-2749.20160106
  • Dergi Adı: Arquivos Brasileiros de Oftalmologia
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.373-375
  • Anahtar Kelimeler: Diabetic complications, Drug therapy, Epiretinal membrane, Macular edema, Ranibizumab/therapeutic use, Retinopathy
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: To investigate the influence of the epiretinal membrane (ERM) on intravitreal ranibizumab (IVR) therapy for diabetic macular edema (DME). Methods: This retrospective study included 56 eyes of 48 patients with DME divided into two groups: the DME with ERM (study) and only DME (control) groups. Changes in the central macular thickness (CMT) and best-corrected visual acuity (BCVA) were evaluated. Results: In the study group, although the CMT was significantly reduced following the first injection (p < 0.001), BCVA did not improve significantly (p=0.296). However, after the first injection, the control group exhibited both a significant decrease in CMT (p < 0.001) and improvement in BCVA (p < 0.001). However, the improvement in BCVA in the control group was not significantly different from the outcome of the study group. Conclusions: We observed a negative short-term influence of the ERM on IVR treatment for DME.